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Aims Chronic heart failure (HF) is a major comorbidity accounting for an increased severity and mortality related to corona-
virus disease 2019 (COVID-19). To reduce the risk of COVID-19 in HF patients, telemedicine has been encouraged.
Methods and results During the COVID-19 pandemic, telemedical management with mainly over-the-phone appointments
became a major strategy of follow-up of our HF clinic patients. Previously, the large majority of patients have been seen in the
hospital with direct patient-provider contact. We compared both strategies of follow-up, in pre-pandemic (PPP) and pandemic
(PP) periods, regarding total mortality and hospitalizations/emergency department (ED) visits due to HF exacerbation. We pro-
spectively studied a cohort of 196 patients. The mean follow-up time in PPP was 1.4 years. In this period, 20 patients died. In
PP (follow-up of 71 days), there was one additional death. Total mortality in the first year of follow-up was 12.0%, matching
the mortality predicted by the Meta-Analysis Global Group in Chronic Heart Failure score. Considering hospitalizations/ED
visits due to decompensated HF, there was no statistically significant difference between PPP and PP. Only one patient was
diagnosed with COVID-19.
Conclusions In the light of an increase in telemedical management of this cohort of HF patients, we were able to maintain a
low rate of admissions due to HF decompensation, without an increment in mortality. Regarding these results, we encourage
the incremental use of telemedicine in HF patients in the context of this or future pandemics and also in situations in which
physical consultation might not be possible due to logistic issues.
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Introduction
On December 2019, a new coronavirus—severe acute respi-
ratory syndrome coronavirus-2 (SARS-CoV-2)—was identified
in Wuhan, China,1 and on March 2020, it has reached pan-
demic levels.2
Although the main manifestation is usually a viral pneumo-
nia, SARS-CoV-2 can also cause cardiovascular complications in
a considerable proportion of patients, such as arterial and ve-
nous thrombotic complications or even acute myocarditis.2–4
Additionally, either patients with cardiovascular risk factors
(male gender, advanced age, arterial hypertension, diabetes
mellitus, and obesity) or patients with established cardiovas-
cular and cerebrovascular disease have been identified as
vulnerable populations with increased morbidity and mortal-
ity in the context of coronavirus disease 2019 (COVID-19).2,5
Moreover, the risk of SARS-CoV-2 infection may be higher
in chronic heart failure (HF) patients, considering that a great
proportion has advanced age and the presence of multiple
comorbidities is frequent.2
Finally, in order to reduce the risk of exposure to SARS-
CoV-2, while preventing patient’s baseline health from deteri-
orating at the same time, telemedical follow-up of stable HF
patients is recommended, reserving direct patient-provider
contact for the emergent/urgent situations.2,6
However, the impact of this strategy, which does not cor-
respond to the standard of care, has not been addressed so
far, therefore driving our current study.
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Methods
Study population, setting, and data collection
The study population consisted of a prospective cohort of pa-
tients with chronic HF followed at a single centre (community
hospital that covers an area of 600 908inhabitants). This cen-
tre has an established HF clinic (HFC), since November 2018,
which currently follows more than 200 patients, mainly with
reduced left ventricular ejection fraction.
This centre is an Electronic Medical Record Adoption
Model stage 7 (Healthcare Information and Management Sys-
tems Society Analytics’ highest stage certification) and a Joint
Commission International-accredited hospital, which facili-
tated the systematization of all the electronic registries and
also the creation of an informatic tool that generates an alert
email every time one of the HFC patients is admitted to the
hospital. ‘Emergency department (ED) visits due to HF
decompensation’ were defined as admissions to the
observation room, with the need for intravenous diuretics
(particularly furosemide), whereas ‘hospitalizations’ were de-
fined as admissions to the ward for intravenous diuretics or
to the intensive care unit for inotropic support.
We prospectively followed all the patients included in our
HFC, from 1 November 2018 to 22 May 2020.
In the pre-pandemic period (from 1 November 2018 to 12
March 2020), the standard follow-up of the patients consisted
of in-person appointments (minimum of one appointment per
trimester) with a multidisciplinary approach, including HF
trained nurse evaluation, HF physician consultation (by a car-
diologist dedicated to HF), with the support of other special-
ties (internal medicine, respiratory medicine, psychiatry,
nephrology, gastroenterology, and nutrition).
All patients in our clinic have also access to a specific phone
number (cell phone allocated to the nurse staff) in order to
contact the team in case of any alert sign or symptom
—according to the action plan (Appendix 1) defined in the
pocket book elaborated by the HFC team as a
self-monitoring registry of vital signs, symptoms, and weight
and as a learning instrument for the patients. There is also a
dedicated email of the HFC to facilitate communication.
In some cases, follow-up phone calls are scheduled to
check patients’ symptoms and to eventually adjust HF drugs,
mainly diuretics. Whenever necessary, according to conges-
tion signs and poor response to oral diuretics, patients are
admitted to our day hospital in order to have intravenous di-
uretics (guided by a pre-specified protocol).
During the pandemic period (from 13 March to 22 May
2020), the in-person appointments were drastically reduced,
being limited to urgent situations and to patients in New York
Heart Association (NYHA) functional classes III/ambulatory IV.
To simplify our approach, all the pre-scheduled appoint-
ments were converted to teleconsultations (over-the-phone
appointments including drug prescription via email or short
message service, with adjustments of drugs in the ambula-
tory setting) in order to identify which patients would need
an in-person care. All teleconsultations were free of charge
for the patients (the government decided to include the ex-
penses related to the teleconsultations in the National Health
Service budget).
In order to check drug adherence, apart from the tele-
phonic inquiry by the HFC team, we monitored the need for
drug prescription renewal.
Every time that the HF team had difficulty reaching any pa-
tient by phone, there was a request to the administrative
staff to contact the patient later on, in order to avoid absence
of clinical evaluation.
To cope with this out-of-hospital management of the ma-
jority of the patients (who were mainly NYHA class I and II),
many blood tests were made in local laboratories, allowing in-
clusively home-based phlebotomy.
Regarding other elective diagnostic and therapeutic proce-
dures, if considered an urgent/emergent situation, it was pos-
sible to do radiographs/computed tomography, transthoracic
or transesophageal echocardiograms, coronary angiograms,
implantation or interrogation of cardiac devices, and inclusion
on heart transplantation list, but all the stress tests had to be
cancelled (including exercise stress test, myocardial scintigra-
phy, stress echocardiography) due to COVID-19 constraints.
Finally, all patients included in this study freely signed an
informed consent form (that has been approved by the
institutional ethics committee) authorizing prospective data
collection for research purposes.
Statistical analysis
Data analysis was performed using Stata version 14.
For categorical variables, we calculated frequencies and
percentages, and for continuous variables, we calculated
mean and standard deviation or median and interquartile
range.
Proportional Student’s t-tests were used to analyse the dif-
ferences between real mortality and estimated mortality.
Chi-squared tests were used to compare ED visits and
hospitalizations.
Kaplan–Meier survival curve was computed to analyse gen-
eral survival.
Significance level was set at 0.05.
Results
Demographic and clinical characteristics of the
patients
Information regarding the demographic and clinical
characteristics of the patients was obtained in the last
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appointment before the pandemic and is presented in
Table 1. The majority of patients received target doses of
HF medication in accordance with the current guidelines.7,8
Outcomes in the pre-pandemic vs. pandemic
period
In the pre-pandemic period, a total of 160 patients (mean of
10 per month) vs. 43 patients (mean of 20 per month), during
the pandemic, had at least one inbound or outbound phone
call with a HF dedicated nurse. The relative percentages of in-
bound/outbound calls were 55%/45% in the pre-pandemic
period and 70%/30% during the pandemic.
Regarding medical evaluation, all of the pre-pandemic ap-
pointments were inpatient, and during the pandemic, more
than 80% of the appointments were done over the phone.
By the end of the pandemic period, there was only one pa-
tient that we were not able to reach out by phone, and in this
case, an in-person appointment was scheduled, via mail post.
We were able to successfully titrate HF medications, such
as sacubitril/valsartan, with a close monitoring of ambulatory
blood tests results (regarding serum creatinine and potassium
levels), registry of blood pressure, weight, and symptoms by
the patients. During the follow-up time, we did not notice
an increased rate of adverse drug events.
The total mortality in the first year of follow-up of this co-
hort was 12.0%, which was not significantly different than the
mortality predicted by the Meta-Analysis Global Group in
Chronic Heart Failure risk score at 1 year (mean value of
12.0% with 6.9% standard deviation).
In the whole pre-pandemic period, there were a total of 20
deaths, and during the pandemic, there was only one
additional death, translating into the following survival curve
(Figure 1).
Regarding hospitalizations (Figure 2) and ED visits (Figure 3)
due to HF decompensation, there was no statistically signifi-
cant difference between the pre-pandemic and the pandemic
period (HF hospitalizations: P = 0.83; ED visits: P = 0.27).
Furthermore, during the pre-pandemic period, there were
seven patients hospitalized and 20 patients treated in the ED
due to HF exacerbation, compared with three patients hospi-
talized and four patients treated in the ED during the pan-
demic period.
As noted with the population admitted for decompensated
HF, the proportion of patients hospitalized due to other diag-
nosis not HF related was also largely superior during the
pre-pandemic period (71 hospitalized and 214 treated in the
ED during the pre-pandemic period vs. 11 hospitalized and
52 treated in the ED during the pandemic period).
Across the pandemic period, there was only one patient di-
agnosed with COVID-19 who was infected in the hospital, in
Table 1 Clinical and demographic characteristics of the patients
Characteristic N = 196
Age (years) 71.4 ± 11.8
Male gender, no. (%) 134 (68%)
Systolic blood pressure (mm Hg) 125 ± 18
Heart rate (beats/min) 65 ± 12




IV (ambulatory) 2 (1%)
Clinical features of heart failure
Ischaemic aetiology, no. (%) 78 (40%)
Left ventricular ejection fraction (%) 35.6 ± 10.6
Median NT-proBNP (IQR)b (pg/mL) 1590 (800–2693)
Medical history, no. (%)
Arterial hypertension 86 (44%)
Diabetes mellitus 31 (16%)
Dyslipidaemia 39 (20%)
Atrial fibrillation 76 (39%)
Obesityc 29 (15%)
Anaemia 26 (13%)
Chronic kidney disease 55 (28%)
COPD 23 (12%)
Medications, no. (%)
ACEi or ARB 83 (42%)
Sacubitril/valsartan 112 (57%)
Beta-blocker 180 (92%)





Implantable cardioverter-defibrillator 27 (14%)
Cardiac resynchronization therapy 16 (8%)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; COPD, chronic obstructive pulmonary disease.
Plus–minus values are means ± standard deviation.
aNew York Heart Association (NYHA) class reflects the status of pa-
tients in the last in-person appointment during the pre-pandemic
period.
bNT-pro-BNP denotes N-terminal pro-B-type natriuretic peptide
plasma levels expressed as pg/mL (equivalent to ng/L, SI units)
and IQR corresponds to interquartile range.
cObesity is defined as a body mass index (weight in kilogrammes di-
vided by the square of the height in metres) greater than or equal
to 30 kg/m2.
Figure 1 Kaplan–Meier survival curve from 1 November 2018 to 22 May
2020, including the pre-pandemic and the pandemic periods. Dashed line
represents the transition between both periods.
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the context of a non-HF hospitalization, with a favourable
outcome (the patient remained asymptomatic without any
cardiovascular or respiratory complications).
Discussion
In Portugal, a state of national emergency was declared from
18 March to 2 May 2020, which implied that only essential
services were able to function and the general population
was advised to stay at home, having a profound impact on
the hospitals’ workflow.
On the one hand, the entire health system had to be pre-
pared to face the pandemic and, on the other hand, needed
to find a solution to keep caring for the higher-risk patients,
including HF patients.
In this context, we immediately adapted our HFC, in order
to keep the follow-up of stable patients with the minimum
physical contact possible, reserving the in-person evaluation
and interventions to unstable patients/urgent situations.
The importance of HFCs in patients’ outcomes has already
been underlined.9–11
Nonetheless, although we also had recently documented a
positive impact of our multidisciplinary model on both the
quality of life and the morbidity/mortality of HF patients,
those results were obtained in a different context, with a fully
operational HFC.12
In this context, we decided to compare the data before
and during the more restrictive phase of the pandemic, in or-
der to evaluate the impact of the change from the previous
model with documented clinical success regarding the al-
ready mentioned outcomes.
During the pandemic, we heavily intensified the number of
teleconsultations of the patients and we were able to man-
age the majority of them without the need of exposure to
the hospital environment.
Despite the significant reduction of in-person consultation
and of total hospital admissions (probably as a result of fear
of COVID-19), there were no increments in hospitalizations
and ED visits due to HF decompensation and no rise in
all-cause mortality, which signals that this approach was safe
and effective, allowing simultaneously protection of the pa-
tients against exposure to SARS-CoV-2.
However, there are some limitations to our study: it is a
single-centre observational study, with a small sample size,
a short period of follow-up during the pandemic compared
with our pre-pandemic period (71 vs. 498 days), and a low
event number.
In the face of these preliminary, real-world, positive re-
sults, we encourage the incremental use of telemedicine in
HF patients, in the context of COVID-19 pandemic or even fu-
ture pandemics. It is feasible, safe, effective, and also more
efficient in terms of access to a frequently overloaded health
system. In the near future, this approach could even be ex-
panded to situations in which physical consultation might
not be possible due to logistics issues, such as patients who
have limited mobility or who have to travel long distances
to reach the hospital.
Finally, COVID-19 pandemic demonstrated the need for a
paradigm shift in standard care, increasing the application
of strategies that keep the patients away from the hospital
as much as possible, avoiding not only the risks inherent to
hospital setting but also the constraints associated to a more
complex level of health care.
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Figure 2 Hospitalizations due to heart failure (HF) decompensation vs.
due to other causes (not HF related) in the pre-pandemic period (PPP)
and during the pandemic period (PP). P = ns denotes a non-significant P
value.
Figure 3 Emergency department (ED) visits due to heart failure (HF) de-
compensation vs. due to other causes (not HF related) in the
pre-pandemic period (PPP) and during the pandemic period (PP). P = ns
denotes a non-significant P value.
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